RNA interference (RNAi) is a fundamental cellular mechanism that regulates gene expression by inducing sequence-specific mRNA degradation. Researchers could utilize the RNAi as a powerful tool to ...

The discovery of RNAi dates back to the 1990s when researchers observed unexpected gene silencing in plants and fungi. In 1998, Andrew Fire and Craig Mello published a groundbreaking study ...

This week's round-up of pharma licensing deals features alliances involving Tenaya Therapeutics, Sino Bio, Antengene, and A2A ...

RNA interference (RNAi) therapeutics have garnered significant attention in clinical research due to their potential for treating various diseases, including genetic disorders, viral infections and ...

Discover six RNAi biotech companies helping to drive momentum in a field that can precisely target disease at its genetic root.

A new possibility for managing cardiovascular disease through RNA interference (RNAi) gene therapies. As cardiovascular diseases continue to be the leading cause of death globally, this technology ...

Alnylam Pharmaceuticals (NasdaqGS:ALNY) has signed a multi year research collaboration with Tenaya Therapeutics focused on RNAi based therapeutics for cardiovascular diseases. The agreement covers up ...

Arrowhead Pharmaceuticals’ RNA interference (RNAi) therapeutic lowered triglycerides in patients with a rare metabolic disease that prevents the body from breaking down fats during a phase 3 trial.

Scientists at the University of California, Riverside have developed a new, RNA-based vaccine strategy that could be effective against just about any strain of a virus, and can be used safely even for ...